Selective intracoronary administration of nitroprusside before balloon dilatation prevents slow reflow during percutaneous coronary intervention in patients with acute myocardial infarction

被引:30
|
作者
Shinozaki, Norihiko [1 ]
Ichinose, Hiroyuki [1 ]
Yahikozawa, Kumiko [1 ]
Shimada, Hirohide [1 ]
Hoshino, Kazuo [1 ]
机构
[1] Naganoken Koseiren Shinoni Gen Hosp, Dept Cardiol, Nagano 388, Japan
关键词
nitroprusside; slow reflow; no reflow; primary angioplasty; percutaneous coronary intervention; acute myocardial infarction;
D O I
10.1536/ihj.48.423
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Previous studies have shown that intracoronary nitroprusside injection is safe and effective after slow reflow complicates percutancous coronary intervention (PCI). Objectives: We sought to determine the safety and efficacy of selective intracoronary administration of nitroprusside through the drug delivery catheter before balloon dilatation to prevent no or slow reflow during PCI for acute myocardial infarction (AMI). Methods: We studied 120 consecutive patients with AMI treated by PCI. In 60 patients (nitroprusside group), nitroprusside (120 mu g) was selectively administered through the drug delivery catheter into the distal coronary artery to reach the target lesion before balloon dilatation. Clinical and angiographic data, as well as in-hospital outcomes, of the nitroprusside group were retrospectively compared with 60 patients who had conventional PCI without nitroprusside (control group). Results: There were no significant differences in the baseline clinical and angiographic characteristics between the 2 groups. Compared to the control group, the nitroprusside group had 1) less slow reflow during the procedure (12% versus 35%, P = 0.0025), 2) a shorter fluoroscopic time (14.4 +/- 7.9 versus 18.7 +/- 9.1 minutes, P = 0.0093), 3) a shorter procedure time (57.6 +/- 20.6 versus 78.1 +/- 26.4, P < minutes, P < 0.0001), 4) a better final TIMI flow grade (III:II:I:0 = 59:1:0:0 versus 53:6:1:0, P = 0.0284), 5) a betterblush grade (III:II:I:0 = 49:10:1:0 versus 33:15:8:4, P = 0.0006), and 6) a better corrected TIMI coronary flame count (30.8 +/- 13.7 versus 46.5 +/- 44.7, P = 0.0102). There were no particular complications with nitroprusside use. Conclusions: The selective intracoronary administration of nitroprusside prior to PCI is safe and well tolerated, prevents no or slow reflows, and improves reperfusion of the infarcted myocardium.
引用
收藏
页码:423 / 433
页数:11
相关论文
共 50 条
  • [21] A NEW SCORE FOR PREDICTION OF SLOW/NO-REFLOW PHENOMENON DURING PRIMARY PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
    Bakr, Mohamed Abo
    Roshdy, Hisham Samir
    Elawadi, Mohamed Ibrahim Mostafa
    Elshaer, Mohamed Hossam Eldein
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 105 - 105
  • [22] The usefulness of intracoronary electrocardiography during primary percutaneous coronary intervention in patients with acute myocardial infarction
    Kim, U.
    Kim, Y. J.
    Lee, S. H.
    Hong, G. R.
    Park, J. S.
    Shin, D. G.
    Shim, B. S.
    EUROPEAN HEART JOURNAL, 2007, 28 : 561 - 561
  • [23] Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no reflow" phenomenon
    Assali, AR
    Sdringola, S
    Ghani, M
    Denkats, AE
    Yepes, A
    Hanna, GP
    Schroth, G
    Fujise, K
    Anderson, HV
    Smalling, RW
    Rosales, OR
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2000, 51 (01) : 27 - 31
  • [24] Shock Index on Admission Is Associated with Coronary Slow/No Reflow in Patients with Acute Myocardial Infarction Undergoing Emergent Percutaneous Coronary Intervention
    Wang, Qingcheng
    Shen, Huimin
    Mao, Huijuan
    Yu, Fenghua
    Wang, Haiqing
    Zheng, Jianlei
    JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2019, 2019
  • [25] Intracoronary nicardipine as a safe and cost-effective alternative to nitroprusside for slow- or no-reflow during percutaneous coronary intervention
    Pennoyer, Adam
    Jennings, Douglas
    Patel, Amisha
    Kirtane, Ajay
    Ma, Karlene
    PHARMACOTHERAPY, 2016, 36 (12): : E213 - E213
  • [26] EFFECTS OF INTRACORONARY DILTIAZEM AND SODIUM NITROPRUSSIDE ON NO-REFLOW PHENOMENON AFTER PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME
    Zhang-Qiang, C.
    Lang, H.
    Min, Y.
    Hong, W.
    Qiu-lin, Y.
    Lin-Feng, L.
    HEART, 2015, 101 : A40 - A40
  • [27] Effectiveness of different tirofiban administration times in patients with no-reflow myocardial infarction during percutaneous coronary intervention
    Mei, Chaosheng
    Yu, Huiping
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2024, 40 (09) : 1969 - 1974
  • [28] Treating Acute "No-Reflow" with Intracoronary Adenosine in 4 Patients during Percutaneous Coronary Intervention
    Forman, Mervyn B.
    Hou, Dongming
    Jackson, Edwin K.
    TEXAS HEART INSTITUTE JOURNAL, 2008, 35 (04): : 439 - 446
  • [29] Intracoronary Nicorandil and the Prevention of the No-Reflow Phenomenon During Primary Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction
    Qi, Qi
    Niu, Jinghui
    Chen, Tao
    Yin, Hongshan
    Wang, Tao
    Jiang, Zhian
    MEDICAL SCIENCE MONITOR, 2018, 24 : 2767 - 2776
  • [30] Intracoronary fixed dose of nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction
    Zhao, Yu-Jun
    Fu, Xiang-Hua
    Ma, Xiao-Xiao
    Wang, Dong-Ying
    Dong, Qiu-Li
    Wang, Yan-Bo
    Li, Wei
    Xing, Kun
    Gu, Xin-Shun
    Jiang, Yun-Fa
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 6 (02) : 479 - 484